Pinatuzumab vedotin

Pinatuzumab vedotin (INN;[1] development codes DCDT2980S and FCU2703) is a monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Pinatuzumab vedotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD22
Clinical data
Other namesDCDT2980S, FCU2703
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6748H10377N1773O2083S44
Molar mass151081.21 g·mol−1

This drug was developed by Genentech/Roche.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.